Marfan syndrome is a genetic disorder that affects body’s connective tissues. Connective tissues are made up of proteins, especially fibrilin-1, which are responsible for holding the whole body, i.e. organs, tissues, and cells together. Marfan syndrome is caused by the mutation in FBN1 gene which makes protein fibrilin-1. A defect in the fibrilin protein can cause overgrowth in the bones. Moreover, Marfan syndrome primarily affects the cardiovascular system, skeletal system, skin, and the eyes of humans.
The condition is mostly inherited; however, 25% of the time it is a new (de novo) mutation. According to the National Human Genome Research Institute, globally one in every 10,000 to 20,000 individuals develop Marfan syndrome. People with Marfan syndrome are very tall, with long, thin arms and legs, with spider like fingers, referred as arachnodactyly. Other symptoms include myopia, ectopia lentis, glaucoma, retinal detachment, and early cataract formation. Additionally, bone overgrowth, loose joints, curvature of the spine (scoliosis), mitral valve prolapse, aortic dissection, and tricuspid valve prolapse are also observed in affected individuals.
Marfan syndrome is difficult to diagnose because its signs and symptoms can vary from person to person. Diagnosis can be carried out through physical examination, medical history, eye examination, chest X-ray, MRI scan, genetic testing, prenatal testing, and preimplantation genetic testing. The Marfan syndrome cannot be cured, but patients can live long, full life with proper treatment and/or management. There is no medical treatment to reverse the fibrillin abnormality in people with Marfan syndrome. Medications that can decrease the pressure inside the aorta such as beta blockers and angiotensin blockers are mostly prescribed. Beta blockers such as propranolol, metoprolol, and atenolol decrease the strain on the aorta by reducing force of contraction. Angiotensin blockers act primarily by lowering blood pressure, which reduces the stress on artery walls.
Request a Brochure of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=43697
Prevalence of Marfan syndrome is more common in infants as it is hereditary. Emergence of new technologies, favorable government initiatives, and availability of favorable reimbursement policies for high-cost therapies are projected to drive the global Marfan syndrome treatment market in the near future. However, high cost of drugs and availability of limited scientific data on the treatment and cure of Marfan syndrome are likely to restrain the global Marfan syndrome treatment market.
The global Marfan syndrome treatment market can be segmented based on treatment type, route of administration, distribution channel, and region. In terms of treatment type, the global market can be categorized into heart treatment such as aortic dilation, drugs treatment such as beta blocker, calcium channel blocker & ACE blocker, surgery, bone and joints treatment, eye treatment, and others. Based on route of administration, the global Marfan syndrome treatment market can be bifurcated into oral and injectable. In terms of distribution channel, the market can be divided into retail pharmacies, hospital pharmacies, and online pharmacies.
Geographically, the global Marfan syndrome treatment market can be segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North America is expected to account for the largest share of the global market due to high expenditure on health care and easy diagnosis and availability of drugs. Europe is expected to be the second largest market for Marfan syndrome treatment during the forecast period due to drug availability and adoption of new treatment methods. The Marfan syndrome treatment market in Asia Pacific is expected to expand rapidly during the forecast period. Growth of the market in the region can be attributed to rapidly developing health care infrastructure.
Key players operating in the global Marfan syndrome treatment market are Sanis Health, Inc., Novartis Pharmaceuticals Corporation, Baxter Healthcare Corporation, Sanofi, Merck & Co., Inc., ANI Pharmaceuticals, Inc., Validus Pharmaceuticals, Inc., and AstraZeneca, among others.
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453
Email: [email protected]